Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Sep 14;12(19):19414–19422. doi: 10.1002/cam4.6536

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Survival outcome of nmCRPC patients treated with abiraterone plus prednisone and enzalutamide. (A) Confirmed PSA responses at 4 (upper panel) and 12 (lower panel) weeks after treatment initiation of enzalutamide (Enz) and abiraterone acetate (AA) plus prednisone. (B) Kaplan–Meier curves of time to PSA progression (TTPP) from treatment initiation. (C) Sankey diagram of the treatment sequences in nmCRPC patients treated with first‐line enzalutamide (n = 69) and abiraterone acetate plus prednisone (n = 64). (D) Kaplan–Meier curve of overall survival from treatment initiation of ARSIs in 133 nmCRPC patients (E, F) Kaplan–Meier curves of cancer‐specific survival (E) and overall survival (F) from treatment initiation of enzalutamide (n = 69) and abiraterone acetate plus prednisone (n = 64) in nmCRPC patients.